SCHEMBL3823929

SCHEMBL3823929

COc1ccc(S(=O)(=O)N2CCN(C(C)c3nc4ccc(NC(C)=O)cc4c(=O)n3C)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.49
▸ PKM P14618 3/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ MEN1 O00255 5/20 0.45
▸ KMT2A Q03164 5/20 0.45
▸ MAPT P10636 4/20 0.45
▸ LMNA P02545 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ USP2 O75604 1/20 0.45
▸ CFTR P13569 1/20 0.44
▸ THRB P10828 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15457178 0.88 CFTR (0.50) KDM4EPKMSMN1; SMN2NPC1TSHR
SCHEMBL3822460 0.85 CFTR (0.48) KDM4EPKMSMN1; SMN2NPC1TSHR
SCHEMBL3820236 0.85 CFTR (0.45) PKMNPC1RAB9AMEN1KMT2A
SCHEMBL3817436 0.85 CFTR (0.47) KDM4EPKMSMN1; SMN2NPC1TSHR
SCHEMBL15457114 0.85 CFTR (0.47) KDM4EPKMSMN1; SMN2NPC1TSHR
SCHEMBL3819087 0.85 CFTR (0.47) KDM4EPKMSMN1; SMN2NPC1TSHR
SCHEMBL15457243 0.85 KMT2A (0.57) KDM4EPKMTSHRHSD17B10MEN1
SCHEMBL15457177 0.84 CFTR (0.46) KDM4EPKMSMN1; SMN2NPC1TSHR
SCHEMBL15457179 0.83 CFTR (0.49) KDM4EPKMNPC1TSHRRAB9A
SCHEMBL15457180 0.83 S1PR1 (0.46) KDM4EPKMSMN1; SMN2NPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 — — EP disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 — — EP disclosed
EP-1646615-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2006-04-19 — — EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 — — US disclosed
WO-2004111014-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCC2 KDM4E 4337/4885PKM 2518/4885SMN1; SMN2 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback